3-喹噁啉-2-丙酸 | 1500-99-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 3-喹噁啉-2-丙酸
• 中文别名: 喹喔啉-3-丙酸
• 英文名称: β-(2-Chinoxalinyl)-propionsaeure
• 英文别名: 3-(Quinoxalin-2-yl)propanoic acid；3-quinoxalin-2-ylpropanoic acid
• CAS: 1500-99-8
• 化学式: C₁₁H₁₀N₂O₂
• 分子量: 202.213
• InChiKey: NVVKLYVOIQWTAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  63.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  3-喹噁啉-2-丙酸 在 双氧水 、 溶剂黄146 作用下， 生成 3-(4-oxy-quinoxalin-2-yl)-propionic acid
  参考文献：
  名称：

  Elina, Zhurnal Obshchei Khimii, 1958, vol. 28, p. 1378,1382;engl.Ausg.S.1437,1439

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(bromomethyl)quinoxaline 在 甲苯 作用下， 生成 3-喹噁啉-2-丙酸
  参考文献：
  名称：

  Elina, Zhurnal Obshchei Khimii, 1959, vol. 29, p. 2763,2765; engl. Ausg. S. 2728, 2729

  摘要：

  DOI：

文献信息

• HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Campbell John Emmerson

  公开号：US20130158003A1

  公开（公告）日：2013-06-20

  Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.

  本文提供了杂环芳基化合物、其合成方法、包含该化合物的药物组合物以及使用该化合物的方法。在一种实施例中，本文提供的化合物可用于治疗、预防和/或管理各种疾病，例如中枢神经系统疾病和代谢性疾病，包括但不限于神经系统疾病、精神病、精神分裂症、肥胖症和糖尿病。
• Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
  申请人：Campbell John Emmerson

  公开号：US08969349B2

  公开（公告）日：2015-03-03

  Provided herein are compounds of formula A-L-B, and pharmaceutically acceptable salts and stereoisomers thereof, wherein A is R1 and R2 together with the carbon atoms to which they are attached form a 1,2-phenylene ring optionally substituted with one or more R11; L is —C(R6)2—C(R6)2—; B is a heteroaromatic group defined herein; and -A1-A2- , A3, R11 and R6 are defined herein. Also disclosed are methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.

  本文提供了A-L-B式化合物及其药学上可接受的盐和立体异构体，其中A为R1和R2，与它们连接的碳原子形成一个可选择地取代一个或多个R11的1,2-苯撑环；L为—C（R6）2—C（R6）2—；B为在本文中定义的杂环芳基；-A1-A2-、A3、R11和R6在本文中定义。还披露了它们的合成方法、包含这些化合物的药物组合物以及它们的使用方法。在一个实施例中，本文提供的化合物可用于治疗、预防和/或管理各种疾病，如中枢神经系统疾病和代谢性疾病，包括但不限于神经系统疾病、精神病、精神分裂症、肥胖症和糖尿病。
• Heteroaryl Compounds and Methods of Use Thereof
  申请人：SUNOVION PHARMACEUTICALS INC.

  公开号：US20150166571A1

  公开（公告）日：2015-06-18

  Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.

  本文提供了杂环芳基化合物、它们的合成方法、包含这些化合物的药物组合物以及它们的使用方法。在一种实施方式中，本文提供的化合物可用于治疗、预防和/或管理各种疾病，例如中枢神经系统疾病和代谢性疾病，包括但不限于神经系统疾病、精神病、精神分裂症、肥胖症和糖尿病等。
• Preparation of lactams from aliphatic - dinitriles
  申请人：E.I. DUPONT DE NEMOURS AND COMPANY

  公开号：EP1449830A1

  公开（公告）日：2004-08-25

  A process for the preparation of five-membered or six-membered ring lactams from aliphatic α,ω-dinitriles has been developed. In the process an aliphatic α,ω-dinitrile is first converted to an ammonium salt of an ω-nitrilecarboxylic acid in aqueous solution using a catalyst having an aliphatic nitrilase (EC 3.5.5.7) activity, or a combination of nitrile hydratase (EC 4.2.1.84) and amidase (EC 3.5.1.4) activities. The ammonium salt of the ω-nitrilecarboxylic acid is then converted directly to the corresponding lactam by hydrogenation in aqueous solution, without isolation of the intermediate ω-nitrilecarboxylic acid or ω-aminocarboxylic acid. When the aliphatic α,ω-dinitrile is also unsymmetrically substituted at the α-carbon atom, the nitrilase produces the ω-nitrilecarboxylic acid ammonium salt resulting from hydrolysis of the ω-nitrile group with greater than 98% regioselectivity, thereby producing only one of the two possible lactam products during the subsequent hydrogenation. A heat-treatment process to select for desirable regioselective nitrilase or nitrile hydratase activities while destroying undesirable activities is also provided.

  我们开发了一种从脂肪族 α,ω-二腈制备五元环或六元环内酰胺的工艺。在该工艺中，首先在水溶液中使用具有脂肪族硝化酶（EC 3.5.5.7）活性或兼具腈水解酶（EC 4.2.1.84）和酰胺酶（EC 3.5.1.4）活性的催化剂将脂肪族 α,ω-二腈转化为ω-腈羧酸的铵盐。然后，ω-腈羧酸的铵盐在水溶液中通过氢化作用直接转化为相应的内酰胺，而无需分离中间体ω-腈羧酸或ω-氨基羧酸。当脂肪族α,ω-二腈在α-碳原子上也被非对称取代时，硝化酶水解ω-腈基产生的ω-腈羧酸铵盐的区域选择性超过 98%，从而在随后的氢化过程中只产生两种可能内酰胺产物中的一种。此外，还提供了一种热处理工艺，用于选择理想的区域选择性腈酶或腈水解酶活性，同时破坏不理想的活性。
• Preparation of lactams from aliphatic alpha,omega dinitriles
  申请人：E.I.Du Pont de Nemours and Company

  公开号：EP1466971A1

  公开（公告）日：2004-10-13

  A process for the preparation of five-membered or six-membered ring lactams from aliphatic α,ω-dinitriles has been developed. In the process an aliphatic α,ω-dinitrile is first converted to an ammonium salt of an ω-nitrilecarboxylic acid in aqueous solution using a catalyst having an aliphatic nitrilase (EC 3.5.5.7) activity, or a combination of nitrile hydratase (EC 4.2.1.84) and amidase (EC 3.5.1.4) activities. The ammonium salt of the ω-nitrilecarboxylic acid is then converted directly to the corresponding lactam by hydrogenation in aqueous solution, without isolation of the intermediate ω-nitrilecarboxylic acid or ω-aminocarboxylic acid. When the aliphatic α,ω-dinitrile is also unsymmetrically substituted at the α-carbon atom, the nitrilase produces the ω-nitrilecarboxylic acid ammonium salt resulting from hydrolysis of the ω-nitrile group with greater than 98% regioselectivity, thereby producing only one of the two possible lactam products during the subsequent hydrogenation. A heat-treatment process to select for desirable regioselective nitrilase or nitrile hydratase activities while destroying undesirable activities is also provided.

  我们开发了一种从脂肪族 α,ω-二腈制备五元环或六元环内酰胺的工艺。在该工艺中，首先在水溶液中使用具有脂肪族硝化酶（EC 3.5.5.7）活性或兼具腈水解酶（EC 4.2.1.84）和酰胺酶（EC 3.5.1.4）活性的催化剂将脂肪族 α,ω-二腈转化为ω-腈羧酸的铵盐。然后，ω-腈羧酸的铵盐在水溶液中通过氢化作用直接转化为相应的内酰胺，而无需分离中间体ω-腈羧酸或ω-氨基羧酸。当脂肪族α,ω-二腈在α-碳原子上也被非对称取代时，硝化酶水解ω-腈基产生的ω-腈羧酸铵盐的区域选择性大于 98%，从而在随后的氢化过程中只产生两种可能内酰胺产物中的一种。此外，还提供了一种热处理工艺，用于选择理想的区域选择性硝化酶或腈水解酶活性，同时破坏不理想的活性。